Scrip
Questions remain about Provenge, says NEJM editorial
29 July 2010
Malini Guha
Please Login to read the full article.
29 July 2010
Malini Guha
Malini.guha@informa.com
The publication of the pivotal IMPACT trial of Dendreon's Provenge (sipuleucel-T) in the NEJM has highlighted that many questions still surround the first therapeutic vaccine to be approved in the US.
In April, the FDA finally gave the green light for Dendreon to market the vaccine...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Relief for Dendreon on upcoming US Medicare coverage meeting on Provenge
- BMS's novel immunotherapy ipilimumab could gain US approval this year for melanoma
- BMS's immunotherapy ipilimumab shows survival benefit in Phase III advanced melanoma trial
- Debate over GSK's Avandia rages as FDA gears up for panel meeting
ANALYSIS
- Executive Briefing – Health technology assessment: a brief look at the EU
- Mind over matter - the novel and the new: anticonvulsants
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
